GlaxoSmithKline Pharmaceuticals Limited (IN:GLAXO)
:GLAXO
Top Page
GlaxoSmithKline Pharmaceuticals Limited
(GLAXO)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹2,459.00
▼(-0.98% Downside)
Action:ReiteratedDate:10/28/25
GlaxoSmithKline Pharmaceuticals Limited's strong financial performance is the most significant factor, showcasing robust profitability and efficient cash flow management. However, the technical analysis indicates bearish momentum, and the high P/E ratio suggests potential overvaluation. The absence of earnings call data and corporate events limits further insights.
Positive Factors
Balance Sheet Strength
Extremely low leverage and significant liquidity give the company durable financial flexibility. This allows funding of local manufacturing, R&D, tender participation and working capital without external borrowing, reducing refinancing risk and supporting continuity across regulatory or pricing cycles.
Negative Factors
Opaque Product/Segment Disclosure
Lack of disclosed product and segment detail reduces visibility into revenue drivers, product concentration, patent or lifecycle risk and tender dependencies. That opacity makes it harder to assess long-term sustainability of sales and the impact of any single product or market on future performance.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
Extremely low leverage and significant liquidity give the company durable financial flexibility. This allows funding of local manufacturing, R&D, tender participation and working capital without external borrowing, reducing refinancing risk and supporting continuity across regulatory or pricing cycles.
Read all positive factors
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹397.54B
Dividend Yield2.16%
Average Volume (3M)1.83K
Price to Earnings (P/E)35.4
Beta (1Y)0.72
Revenue Growth4.17%
EPS Growth41.51%
CountryIN
Employees3,211
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)16.70
Shares Outstanding169,406,040
10 Day Avg. Volume1,472
30 Day Avg. Volume1,831
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)24.29
Price to Sales (P/S)12.72
P/FCF Ratio37.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)68.48
Revenue Forecast (FY)₹42.76B
GlaxoSmithKline Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-in...
How the Company Makes Money
GLAXO primarily makes money by selling pharmaceutical products through regulated channels such as hospitals, pharmacies, clinics, and government or institutional procurement programs. Revenue is typically generated from (1) sales of finished pharm...
GlaxoSmithKline Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
80
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.86B | 37.26B | 34.42B | 32.26B | 32.64B | 28.99B |
| Gross Profit | 20.94B | 22.53B | 20.22B | 18.68B | 18.14B | 15.61B |
| EBITDA | 13.68B | 13.28B | 8.88B | 9.04B | 8.49B | 5.36B |
| Net Income | 9.55B | 9.28B | 5.90B | 6.11B | 16.95B | 3.58B |
Balance Sheet | ||||||
| Total Assets | 36.65B | 41.08B | 35.57B | 33.27B | 46.33B | 31.13B |
| Cash, Cash Equivalents and Short-Term Investments | 20.61B | 24.98B | 18.57B | 16.54B | 29.03B | 11.63B |
| Total Debt | 357.10M | 99.50M | 186.65M | 155.40M | 200.76M | 346.27M |
| Total Liabilities | 19.57B | 21.57B | 17.79B | 15.85B | 19.70B | 16.14B |
| Stockholders Equity | 17.08B | 19.51B | 17.78B | 17.41B | 26.63B | 14.78B |
Cash Flow | ||||||
| Free Cash Flow | 1.67B | 12.67B | 5.51B | 4.40B | 7.76B | 5.34B |
| Operating Cash Flow | 1.84B | 12.90B | 5.82B | 4.84B | 8.11B | 5.78B |
| Investing Cash Flow | 3.40B | -458.10M | 87.12M | 8.08B | -4.06B | 4.19B |
| Financing Cash Flow | -7.23B | -7.69B | -5.61B | -15.43B | -5.24B | -6.96B |
GlaxoSmithKline Pharmaceuticals Limited Technical Analysis
Negative
2483.35
Price Trends
2460.43
Negative
2477.35
Negative
2696.17
Negative
Market Momentum
-55.35
Positive
43.37
Neutral
50.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAXO, the sentiment is Negative. The current price of 2483.35 is above the 20-day moving average (MA) of 2394.14, above the 50-day MA of 2460.43, and below the 200-day MA of 2696.17, indicating a bearish trend. The MACD of -55.35 indicates Positive momentum. The RSI at 43.37 is Neutral, neither overbought nor oversold. The STOCH value of 50.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GLAXO.
GlaxoSmithKline Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹4.06T | 30.62 | ― | 0.91% | 9.26% | -5.47% | |
72 Outperform | ₹1.04T | 20.49 | ― | 0.57% | 15.49% | 64.37% | |
70 Outperform | ₹1.02T | 21.88 | ― | 0.63% | 14.10% | 9.72% | |
68 Neutral | ₹970.23B | 45.14 | ― | 0.87% | 6.93% | 21.55% | |
66 Neutral | ₹1.36T | 51.30 | ― | 0.84% | 9.11% | 18.76% | |
63 Neutral | ₹397.54B | 35.44 | ― | 2.16% | 4.17% | 41.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,346.65
-197.39
-7.76%
IN:CIPLA
Cipla Ltd
1,201.10
-168.66
-12.31%
IN:DRREDDY
Dr. Reddy's Laboratories Ltd.
1,217.20
135.41
12.52%
IN:LUPIN
Lupin Limited
2,277.90
366.87
19.20%
IN:SUNPHARMA
Sun Pharmaceutical Industries Limited
1,694.20
42.06
2.55%
IN:TORNTPHARM
Torrent Pharmaceuticals Ltd
4,007.55
803.09
25.06%
GlaxoSmithKline Pharmaceuticals Limited Corporate Events
GSK Pharma India Publishes Postal Ballot Notice Advertisements in Line With LODR Norms
Mar 11, 2026
GlaxoSmithKline Pharmaceuticals Limited has notified the stock exchanges that it has published newspaper advertisements regarding a postal ballot notice, in compliance with Regulation 47 of the Listing Obligations and Disclosure Requirements Regul...
GSK Pharma India Seeks Shareholder Nod on CFO Appointment via E‑Voting
Mar 7, 2026
GlaxoSmithKline Pharmaceuticals Limited has initiated a postal ballot process to seek shareholder approval for the appointment and remuneration of Mr. Ronojit Biswas as Whole-time Director and Chief Financial Officer. The move, conducted entirely ...
GSK Pharma India Seeks Shareholder Nod for CFO Appointment via E-Voting Postal Ballot
Mar 7, 2026
GlaxoSmithKline Pharmaceuticals Limited has initiated a shareholder approval process via an electronic postal ballot to confirm the appointment and remuneration of Mr. Ronojit Biswas as Whole-time Director and Chief Financial Officer. The move und...
GSK Pharma India Names Ronojit Biswas as New CFO Amid Leadership Transition
Mar 2, 2026
GlaxoSmithKline Pharmaceuticals Limited has announced that its board has approved the appointment of Ronojit Biswas as Whole-Time Director and Chief Financial Officer for a three-year term starting April 1, 2026. Biswas, a veteran GSK finance exec...
GSK Pharma India Names Ronojit Biswas CFO as Juby Chandy Moves to APAC Role
Mar 2, 2026
GlaxoSmithKline Pharmaceuticals Limited has announced a leadership change in its finance function, appointing Ronojit Biswas as Whole-Time Director and Chief Financial Officer for a three-year term starting 1 April 2026. Biswas, a long-serving GSK...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.